Mali Barbi, Medical Oncologist at Northwell Health, shared a post on X:
”The 63% majority is clearly leaning on the 14-month DFI and strong CPS 15 to justify an IO re-challenge with the ASCENT–04 regimen, which demonstrated a median PFS of 11.2 months. It is a valid approach, but here is why I am in the 18% betting on Dato-DXd (TROPION–Breast02): With a post-KN522 relapse, immune exhaustion is a major clinical concern.
By intentionally bypassing a questionable IO re-challenge, we still secure robust 1L efficacy a median PFS of 10.8 months compared to 5.6 months with chemotherapy. Deploying the potent DXd payload early also helps us sidestep the severe neutropenia and GI toxicities notoriously driven by SG’s SN-38 payload. It is a highly strategic move to maximize early survival benefits while avoiding overlapping cytopenias.”
To which, Harold Burstein, Breast Cancer Specialist and Professor at Dana-Farber Cancer Institute and at Harvard Medical School, added:
”None of these studies had substantial numbers of pts with prior IO. If recurred post kn522 odds are there was residual disease and she would have had adjuvant capecitabine. Thus 5 prior chemo + IO.”
You can also read ‘Lisa Faulkner and Breast Cancer: Diagnosis, Surgery, and What She Revealed‘
